Dermatology · Linwood, NJ
NPI
1548231228
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1401 New Rd
Linwood, NJ, 08221
Phone (609) 927-5885
Groups this clinician bills Medicare through
Medicare paid, 2024
$265K
4,357 services
Medicare patients, 2024
1,046
Average age 76
Drug cost, 2024
$178K
1,467 prescriptions
Company payments, 2025
$739
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joseph J Hong was code 99213 (office e&m - established), 1,346 times for 843 patients. In total Joseph J Hong billed 4,357 services in 45 codes, and Medicare paid $265K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,346 | 843 | $66.78 | $90K |
| 17003 Destruction Skin Lesion | Office | 709 | 108 | $5.04 | $3,575 |
| 11102 Skin Biopsy | Office | 647 | 499 | $66.98 | $43K |
| 17110 Destruction Skin Lesion | Office | 287 | 250 | $81.59 | $23K |
| 99212 Office E&M - Established | Office | 226 | 185 | $40.92 | $9,248 |
| 11103 Skin Biopsy | Office | 202 | 144 | $38.79 | $7,835 |
| 99203 Office E&M - New | Office | 188 | 188 | $75.92 | $14K |
| 17000 Destruction Skin Lesion | Office | 162 | 142 | $41.38 | $6,703 |
| 99214 Office E&M - Established | Office | 129 | 88 | $94.99 | $12K |
| 17262 Destruction Skin Lesion | Office | 70 | 67 | $129.85 | $9,090 |
| 17004 Destruction Skin Lesion | Office | 64 | 59 | $127.80 | $8,179 |
| 17111 Destruction Skin Lesion | Office | 40 | 34 | $99.00 | $3,960 |
| 67810 Eye | Office | 40 | 39 | $139.88 | $5,595 |
| 10060 Skin | Office | 37 | 37 | $95.80 | $3,545 |
| 17282 Destruction Skin Lesion | Office | 32 | 31 | $152.74 | $4,888 |
By year: 2022 $249K for 3,519 services; 2023 $283K for 3,889 services; 2024 $265K for 4,357 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joseph J Hong prescribed most often to Medicare patients was Ketoconazole, with 243 prescriptions and refills. In total Joseph J Hong wrote 1,467 Medicare prescriptions that cost $178K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 243 | 268 | 148 | $3,959 |
| Hydrocortisone Generic | 143 | 149 | 98 | $673 |
| Triamcinolone Acetonide Generic | 112 | 116 | 96 | $925 |
| Ammonium Lactate Generic | 106 | 115 | 73 | $1,531 |
| Fluocinonide Generic | 101 | 106 | 85 | $3,496 |
| Fluorouracil Generic | 80 | 83 | 66 | $5,031 |
| Metronidazole Generic | 70 | 75 | 45 | $2,484 |
| Cephalexin Generic | 52 | 52 | 50 | $486 |
| Fluocinolone Acetonide Generic | 48 | 51 | 40 | $1,607 |
| Levocetirizine Dihydrochloride Generic | 37 | 67 | 22 | $567 |
| Halobetasol Propionate Generic | 32 | 34 | 19 | $1,615 |
| Selenium Sulfide Generic | 32 | 39 | 25 | $402 |
| Valacyclovir Valacyclovir Hcl | 28 | 30 | 16 | $262 |
| Montelukast Sodium Generic | 27 | 41 | 21 | $240 |
| Jublia Efinaconazole | 27 | 29 | 14 | $32K |
Brand drugs: - claims; generic drugs: 1,322 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph J Hong $739 ($739 in general payments such as food, travel and fees) from 11 companies. The largest payer was Janssen Biotech, Inc. with $170.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 7 | $170 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $98.46 |
| Genzyme Corporation SNY | 4 | $87.51 |
| Incyte Corporation INCY | 4 | $81.27 |
| Abbvie Inc. ABBV | 2 | $58.1 |
| UCB, Inc. UCB.BR | 3 | $54.15 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $53.99 |
| Lilly USA, LLC LLY | 3 | $48.85 |
| Galderma Laboratories, L.P. GALD.SW | 3 | $46.73 |
| SpringWorks Therapeutics, Inc. | 1 | $23.16 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.